Merz Company Profile
What is the competitive landscape for MERZ
MERZ has four approved drugs.
There are six US patents protecting MERZ drugs.
Summary for Merz
| US Patents: | 6 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
| Patent Litigation for Merz: | See patent lawsuits for Merz |
Drugs and US Patents for Merz
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,945,612 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,545,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | RE43711 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 9,393,210 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,685,442 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merz
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 7,182,961 | ⤷ Start Trial |
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 6,514,482 | ⤷ Start Trial |
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 6,921,528 | ⤷ Start Trial |
| Merz | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 8,663,685 | ⤷ Start Trial |
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | 7,638,552 | ⤷ Start Trial |
| Merz | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 8,404,276 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERZ drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/5 mL | ➤ Subscribe | 2012-06-20 |
| ➤ Subscribe | Extended-release Tablets | 10 mg | ➤ Subscribe | 2014-01-22 |
International Patents for Merz Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2908805 | ⤷ Start Trial |
| South Korea | 102337781 | ⤷ Start Trial |
| Denmark | 2630954 | ⤷ Start Trial |
| Canada | 2888994 | ⤷ Start Trial |
| Spain | 2487816 | ⤷ Start Trial |
| South Korea | 20150110480 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merz Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435024 | 21C1020 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| 2435025 | LUC00124 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 3209302 | 2023C/510 | Belgium | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: BE660571 20220901 |
| 3209302 | 23C1035 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE FOSLEVODOPA ET DE FOSCARBIDOPA, CHACUNE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; NAT. REGISTRATION NO/DATE: 34009 302 790 8 3 20230901; FIRST REGISTRATION: AT - 141371 20220826 |
| 2435025 | 1990034-9 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALT OR ESTERS THEREOF AND FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS THEREOF.; REG. NO/DATE: EU/1/18/1339 20181220 |
| 3209302 | 122023000043 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON FOSLEVODOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON MIT FOSCARBIDOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; NAT. REGISTRATION NO/DATE: 7005976.00.00 20230223; FIRST REGISTRATION: OESTERREICH 141371 20220825 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
